Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 2
2005 4
2006 2
2007 3
2008 1
2010 1
2011 2
2012 1
2013 1
2014 2
2015 1
2016 4
2017 2
2018 1
2019 1
2020 5
2021 5
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.
Scaglione GL, Pignata S, Pettinato A, Paolillo C, Califano D, Scandurra G, Lombardo V, Di Gaudio F, Pecorino B, Mereu L, Scollo P, Capoluongo ED. Scaglione GL, et al. Among authors: califano d. Int J Mol Sci. 2023 Dec 4;24(23):17095. doi: 10.3390/ijms242317095. Int J Mol Sci. 2023. PMID: 38069422 Free PMC article.
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab.
Polano M, Bedon L, Dal Bo M, Sorio R, Bartoletti M, De Mattia E, Cecchin E, Pisano C, Lorusso D, Lissoni AA, De Censi A, Cecere SC, Scollo P, Marchini S, Arenare L, De Giorgi U, Califano D, Biagioli E, Chiodini P, Perrone F, Pignata S, Toffoli G. Polano M, et al. Among authors: califano d. Clin Pharmacol Ther. 2023 Sep;114(3):652-663. doi: 10.1002/cpt.2960. Epub 2023 Jun 21. Clin Pharmacol Ther. 2023. PMID: 37243926
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Among authors: califano d. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial.
Forlani L, De Cecco L, Simeon V, Paolini B, Bagnoli M, Cecere SC, Spina A, Citeroni E, Bignotti E, Lorusso D, Arenare L, Russo D, De Angelis C, Ardighieri L, Scognamiglio G, Del Sesto M, Tognon G, Califano D, Schettino C, Chiodini P, Perrone F, Mezzanzanica D, Pignata S, Tomassetti A. Forlani L, et al. Among authors: califano d. J Exp Clin Cancer Res. 2023 Apr 11;42(1):83. doi: 10.1186/s13046-023-02651-y. J Exp Clin Cancer Res. 2023. PMID: 37041632 Free PMC article.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Musacchio L, Turinetto M, Arenare L, Bartoletti M, Califano D, Tuninetti V, Marchetti C, Cormio G, Loizzi V, Pisano C, Salutari V, Valabrega G, Priolo D, Cecere SC, Ventriglia J, Raspagliesi F, Perrone F, Fagotti A, Lorusso D, Scambia G, Pignata S. Musacchio L, et al. Among authors: califano d. Gynecol Oncol. 2023 May;172:72-77. doi: 10.1016/j.ygyno.2023.03.011. Epub 2023 Mar 23. Gynecol Oncol. 2023. PMID: 36965291
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.
Fabbi M, Costa D, Russo D, Arenare L, Gaggero G, Signoriello S, Scambia G, Pisano C, Colombo N, Losito NS, Filaci G, Spina A, Califano D, Scognamiglio G, Gadducci A, Mezzanzanica D, Bagnoli M, Ferrini S, Canzonieri V, Chiodini P, Perrone F, Pignata S. Fabbi M, et al. Among authors: califano d. Diagnostics (Basel). 2022 Aug 31;12(9):2118. doi: 10.3390/diagnostics12092118. Diagnostics (Basel). 2022. PMID: 36140519 Free PMC article.
Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer.
Passarelli A, Pisano C, Cecere SC, Di Napoli M, Rossetti S, Tambaro R, Ventriglia J, Gherardi F, Iannacone E, Venanzio SS, Fiore F, Bartoletti M, Scognamiglio G, Califano D, Pignata S. Passarelli A, et al. Among authors: califano d. Front Immunol. 2022 Sep 2;13:953115. doi: 10.3389/fimmu.2022.953115. eCollection 2022. Front Immunol. 2022. PMID: 36119020 Free PMC article. Review.
The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
Morra F, Merolla F, Damia G, Ricci F, Varricchio S, Ilardi G, Arenare L, Califano D, Napolitano V, Fruscio R, Melillo RM, Palazzo L, Celetti A. Morra F, et al. Among authors: califano d. J Exp Clin Cancer Res. 2022 Aug 13;41(1):245. doi: 10.1186/s13046-022-02459-2. J Exp Clin Cancer Res. 2022. PMID: 35964058 Free PMC article.
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Musacchio L, Califano D, Bartoletti M, Arenare L, Lorusso D, Losito NS, Cormio G, Greggi S, Raspagliesi F, Valabrega G, Salutari V, Pisano C, Spina A, Russo D, Del Sesto M, Canzonieri V, Ferraù F, Zannoni GF, Loizzi V, Ghizzoni V, Casanova C, Tuninetti V, Ducceschi M, Del Vecchio V, Scalone S, Priolo D, Perrone F, Scambia G, Pignata S. Musacchio L, et al. Among authors: califano d. Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22. Br J Cancer. 2022. PMID: 35869143 Free PMC article.
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.
D'Alterio C, Spina A, Arenare L, Chiodini P, Napolitano M, Galdiero F, Portella L, Simeon V, Signoriello S, Raspagliesi F, Lorusso D, Pisano C, Colombo N, Zannoni GF, Losito NS, De Cecio R, Scognamiglio G, Califano D, Russo D, Tuninetti V, Piccirillo MC, Gargiulo P, Perrone F, Pignata S, Scala S. D'Alterio C, et al. Among authors: califano d. Cancers (Basel). 2022 Apr 6;14(7):1849. doi: 10.3390/cancers14071849. Cancers (Basel). 2022. PMID: 35406620 Free PMC article.
48 results